Suven Life Sciences hits 52-week high after getting nod to incorporate subsidiary in Singapore
Suven Life Sciences is currently trading at Rs. 341.00, up by 23.65 points or 7.45% from its previous closing of Rs. 317.35 on the BSE.
The scrip opened at Rs. 319.00 and has touched a high and low of Rs. 345.90 and Rs. 318.75 respectively. So far 1.18 lakh shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 345.90 on 09-Jul-2026 and a 52 week low of Rs. 124.35 on 24-Mar-2026.
Last one week high and low of the scrip stood at Rs. 345.90 and Rs. 305.15 respectively. The current market cap of the company is Rs. 8983.67 crore.
The promoters holding in the company stood at 70.15%, while Institutions and Non-Institutions held 5.53% and 24.32% respectively.
Suven Life Sciences has received approval to incorporate a wholly owned subsidiary (WOS) namely ‘Suven Neurosciences’ in Singapore. The new entity will be the Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for treatment of neurological and other disorders.
The board of directors of the company, at its meeting held on July 08, 2026, has inter-alia considered and approved the same.
